查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566844

曲安西龙市场：按类型、应用、通路分类：2024-2033 年全球机会分析与产业预测

Triamcinolone Market By Type , By Application By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3个工作天内

价格
简介目录

曲安西龙市场

2023年曲安西龙市场价值为9亿美元，预计2024年至2033年复合年增长率为3.8%，2033年达13亿美元。

曲安西龙是一种具有发炎和免疫抑制特性的糖皮质激素，用于治疗多种疾病，包括过敏反应、皮肤病、关节炎和气喘等呼吸道疾病。该化合物以多种形式存在，可针对身体的特定区域或提供全身作用。这些剂型包括软膏、外用乳膏、口服锭剂、注射剂和滴鼻剂。曲安西龙透过抑制组织胺和细胞激素等发炎物质的释放来帮助减轻肿胀、发红和搔痒。

慢性病盛行率的上升、老年人口的快速成长以及医疗基础设施的扩张是曲安西龙市场的关键驱动因素。老年人更容易患慢性发炎疾病，如关节炎、气喘和皮肤病。曲安西龙是一种有效的皮质类固醇，透过提供有效的发炎和免疫抑製作用，显着减轻此类疾病的症状。透过先进的药物传输系统（例如奈米製剂）施用曲安西龙已成为加速呼吸系统疾病和慢性皮肤疾病恢復过程的治疗方法的趋势。

然而，某些因素正在限製曲安西龙市场的开拓。长期使用或高剂量的皮质类固醇曲安西龙会导致严重的副作用，包括体重增加、皮肤变薄、血糖值升高和感染疾病风险增加。因此，许多医生和患者不喜欢曲安西龙作为药物，限制了市场的成长。相反，曲安西龙被认为是治疗多种健康状况的药物，这表明未来应用的潜力越来越大。根据最新医学资讯网站Medscape近期发表的一篇报导称，曲安西龙是治疗甲状腺眼疾的优秀药物。经皮注射曲安西龙有助于改善这种疾病的边缘反射距离 1 (MRD1) 和上眼睑回缩 (UER)。

按部门审查

曲安西龙市场按类型、应用、分销管道和地区细分。按类型划分，市场分为乳膏剂、注射剂和吸入剂。依用途分为湿疹、皮肤炎、过敏、干癣等。依销售管道分为药局、医院药局、网路药局。从区域来看，分析涵盖北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

按类型划分，奶油细分市场将在 2023 年占据主导地位。

根据申请，湿疹板块是2023年的最大股东。

从分销管道来看，药局细分市场在2023年获得了较高的份额。

按地区划分，由于製药业的成长和医疗保健领域的投资，亚太地区的市场正在迅速扩大。

该报告可以定制（需要单独的费用和时间表）。

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 历史市场资料
  • 主要参与企业的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章曲安西龙市场：依类型

  • 市场概况
  • 奶油
  • 注射
  • 吸入剂

第五章曲安西龙市场：依应用分类

  • 市场概况
  • 湿疹
  • 皮肤炎
  • 过敏
  • 干癣
  • 其他的

第六章曲安西龙市场：按分销管道

  • 市场概况
  • 药局
  • 医院药房
  • 网路药房

第七章曲安西龙市场：依地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国曲安西龙市场
    • 加拿大曲安西龙市场
    • 墨西哥曲安西龙市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国曲安西龙市场
    • 法国曲安西龙市场
    • 英国曲安西龙市场
    • 义大利曲安西龙市场
    • 西班牙曲安西龙市场
    • 其他欧洲曲安奈德市场
  • 亚太地区
    • 主要市场趋势和机会
    • 日本曲安西龙市场
    • 中国曲安西龙市场
    • 澳洲曲安西龙市场
    • 印度曲安西龙市场
    • 韩国曲安西龙市场
    • 其他亚太地区曲安西龙市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西曲安西龙市场
    • 沙乌地阿拉伯曲安奈德市场
    • 南非曲安西龙市场
    • 其他拉丁美洲/中东/非洲曲安西龙市场

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第九章 公司简介

  • Akorn Inc
  • Bristol Myers Squibb Company
  • Cosette Pharmaceuticals, Inc
  • Glenmark Pharmaceuticals
  • Lupin
  • Mylan NV
  • Novartis AG
  • Sun Pharmaceutical Industries Limited
  • Taro Pharmaceutical Industries
  • Teva Pharmaceuticals
简介目录
Product Code: A66219

Triamcinolone Market

The triamcinolone market was valued at $0.9 billion in 2023 and is projected to reach $1.3 billion by 2033, growing at a CAGR of 3.8% from 2024 to 2033.

Triamcinolone is a glucocorticoid with anti-inflammatory and immunosuppressive properties that is used in the treatment of various medical conditions, including allergic reactions, skin disorders, arthritis, and respiratory illnesses such as asthma. The compound exists in multiple forms to target specific areas of the body or provide systemic effects. These forms include ointments, topical creams, oral tablets, injections, and nasal sprays. Triamcinolone helps to reduce swelling, redness, and itching by inhibiting the release of inflammatory substances such as histamines & cytokines.

Increasing prevalence of chronic diseases, exponentially growing geriatric population, and expansion of healthcare infrastructure are the key drivers of the triamcinolone market. The elderly individuals are highly prone to chronic and inflammatory diseases such as arthritis, asthma, and dermatological conditions. Triamcinolone, being a potent corticosteroid, remarkably alleviates the symptoms of such diseases by providing effective anti-inflammatory and immunosuppressive advantages. The administration of triamcinolone through advanced drug delivery systems such as nano formulations is trending in the treatment procedures as it enhances the recovery process for respiratory and chronic skin conditions.

However, certain factors restrain the development of the triamcinolone market. Being a corticosteroid, prolonged usage or high doses of the compound leads to severe side-effects, including weight gain, skin thinning, increase in blood sugar levels, and high risk of infections. This deters several medical practitioners and patients from preferring triamcinolone as a medication, thereby restraining the market growth. On the contrary, triamcinolone is being explored for the treatment for different health conditions, which indicates its enhanced applicability in the future. According to a recent article published by Medscape, a website publishing latest medical information, triamcinolone is an excellent drug for the treatment of thyroid eye disease. Injection of triamcinolone percutaneously helps to improve margin reflex distance 1 (MRD1) and upper eyelid retraction (UER) in the disease.

Segment Review

The triamcinolone market is segmented into type, application, distribution channel, and region. On the basis of type, the market is divided into cream, injection, and inhalers. By application, it is classified into eczema, dermatitis, allergies, psoriasis, and others. As per distribution channel, it is categorized into drug stores, hospitals pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the cream segment dominated market in 2023.

By application, the eczema segment was the highest shareholder in 2023.

As per distribution channel, the drug store segment acquired high stakes in 2023.

Region wise, the market is rapidly expanding in Asia-Pacific owing to the growing pharmaceutical industry and investments in healthcare.

Competition Analysis

The major players operating in the global triamcinolone market include Akorn Inc, Bristol Myers Squibb Company, Cosette Pharmaceuticals, Inc, Glenmark Pharmaceuticals, Lupin, Mylan N.V., Novartis AG, Sun Pharmaceutical Industries Limited, Taro Pharmaceutical Industries, and Teva Pharmaceuticals. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • Cream
  • Injection
  • Inhalers

By Application

  • Eczema
  • Dermatitis
  • Allergies
  • Psoriasis
  • Others

By Distribution Channel

  • Drug Stores
  • Hospitals Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Akorn Inc
    • Bristol Myers Squibb Company
    • Cosette Pharmaceuticals, Inc
    • Glenmark Pharmaceuticals
    • Lupin
    • Mylan N.V.
    • Novartis AG
    • Sun Pharmaceutical Industries Limited
    • Taro Pharmaceutical Industries
    • Teva Pharmaceuticals

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: TRIAMCINOLONE MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Cream
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Injection
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Inhalers
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: TRIAMCINOLONE MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Eczema
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Dermatitis
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Allergies
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Psoriasis
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country
  • 5.6. Others
    • 5.6.1. Key Market Trends, Growth Factors and Opportunities
    • 5.6.2. Market Size and Forecast, By Region
    • 5.6.3. Market Share Analysis, By Country

CHAPTER 6: TRIAMCINOLONE MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Distribution Channel
  • 6.2. Drug Stores
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Hospitals Pharmacies
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Online Pharmacies
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: TRIAMCINOLONE MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Type
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By Distribution Channel
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Triamcinolone Market
      • 7.2.6.1. Market Size and Forecast, By Type
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By Distribution Channel
    • 7.2.7. Canada Triamcinolone Market
      • 7.2.7.1. Market Size and Forecast, By Type
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By Distribution Channel
    • 7.2.8. Mexico Triamcinolone Market
      • 7.2.8.1. Market Size and Forecast, By Type
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Type
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By Distribution Channel
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Triamcinolone Market
      • 7.3.6.1. Market Size and Forecast, By Type
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By Distribution Channel
    • 7.3.7. France Triamcinolone Market
      • 7.3.7.1. Market Size and Forecast, By Type
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By Distribution Channel
    • 7.3.8. UK Triamcinolone Market
      • 7.3.8.1. Market Size and Forecast, By Type
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By Distribution Channel
    • 7.3.9. Italy Triamcinolone Market
      • 7.3.9.1. Market Size and Forecast, By Type
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By Distribution Channel
    • 7.3.10. Spain Triamcinolone Market
      • 7.3.10.1. Market Size and Forecast, By Type
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By Distribution Channel
    • 7.3.11. Rest of Europe Triamcinolone Market
      • 7.3.11.1. Market Size and Forecast, By Type
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Type
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By Distribution Channel
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Triamcinolone Market
      • 7.4.6.1. Market Size and Forecast, By Type
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By Distribution Channel
    • 7.4.7. China Triamcinolone Market
      • 7.4.7.1. Market Size and Forecast, By Type
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By Distribution Channel
    • 7.4.8. Australia Triamcinolone Market
      • 7.4.8.1. Market Size and Forecast, By Type
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By Distribution Channel
    • 7.4.9. India Triamcinolone Market
      • 7.4.9.1. Market Size and Forecast, By Type
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By Distribution Channel
    • 7.4.10. South Korea Triamcinolone Market
      • 7.4.10.1. Market Size and Forecast, By Type
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By Distribution Channel
    • 7.4.11. Rest of Asia-Pacific Triamcinolone Market
      • 7.4.11.1. Market Size and Forecast, By Type
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Type
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By Distribution Channel
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Triamcinolone Market
      • 7.5.6.1. Market Size and Forecast, By Type
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By Distribution Channel
    • 7.5.7. Saudi Arabia Triamcinolone Market
      • 7.5.7.1. Market Size and Forecast, By Type
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By Distribution Channel
    • 7.5.8. South Africa Triamcinolone Market
      • 7.5.8.1. Market Size and Forecast, By Type
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By Distribution Channel
    • 7.5.9. Rest of LAMEA Triamcinolone Market
      • 7.5.9.1. Market Size and Forecast, By Type
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Akorn Inc
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Bristol Myers Squibb Company
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Cosette Pharmaceuticals, Inc
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Glenmark Pharmaceuticals
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Lupin
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Mylan N.V.
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Novartis AG
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Sun Pharmaceutical Industries Limited
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Taro Pharmaceutical Industries
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Teva Pharmaceuticals
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments